Background: Eosinophilic cationic protein (ECP) is associated with airway inflammation and asthma. However, the clinical value of measuring ECP in childhood asthma is not fully known. We aimed to study the diagnostic performance of serum ECP and other common asthma biomarkers, individually and in combinations. Methods: In a cross-sectional study, 5–16-year-old children with current asthma (CA) (n = 37), transient asthma (TA) (n = 43), (previous history of wheezing/asthma), and healthy children (HC) (n = 86) were investigated for ECP, blood eosinophil count (B-Eos), fractional exhaled nitric oxide (FeNO), and lung function, i.e., spirometry (forced expiratory volume during the first second [FEV1]/forced vital capacity [FVC] ratio). Results: Both ECP and B-Eos were higher in CA compared to TA (p < 0.01) and HC (p < 0.0001). ECP and B-Eos were also higher in TA compared to HC (p < 0.05 and p < 0.001, respectively). FeNO was higher in CA (p < 0.0001) and TA (p < 0.01) compared to HC but similar between the asthma groups. The FEV1/FVC ratio was lower in CA compared to TA and HC (both p < 0.01) but similar between TA and HC. The best diagnostic performance regarding CA was found for ECP and B-Eos with receiver operating characteristics area under curve (AUC) of 0.801 and 0.810, respectively. The optimal cutoff for ECP (29 μg/L) yielded a sensitivity and specificity of 70.3% and 81.4%. The corresponding AUCs for FeNO and FEV1/FVC were 0.732 and 0.670, respectively. ECP and B-Eos showed the highest AUCs (0.669 and 0.673) for differentiation between CA and TA. Combining ECP with FeNO and FEV1/FVC increased the odds ratio (OR) for having CA from OR 3.97–10.3 for the single biomarkers to OR 20.2 (95% confidence interval: 5.76–68.6). Conclusion: Our results show that serum ECP is a reliable biomarker in the diagnosis of childhood asthma, with additional value in combination with FeNO and FEV1/FVC, and that ECP can be an alternative to B-Eos.

Keywords:
Serum eosinophilic cationic protein, Blood eosinophil count, Exhaled nitric oxide, Lung function, Childhood asthma
1.
Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy.
J Allergy Clin Immunol
. 1998;102(4 Pt 2):S17–22.
2.
Saglani S, Lloyd CM. Novel concepts in airway inflammation and remodelling in asthma.
Eur Respir J
. 2015;46(6):1796–804.
3.
Pavlidis S, Takahashi K, Ng Kee Kwong F, Xie J, Hoda U, Sun K, et al. “T2-highˮ in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin.
Eur Respir J
. 2019;53(1):1800938.
4.
Kyriakopoulos C, Gogali A, Bartziokas K, Kostikas K. Identification and treatment of T2-low asthma in the era of biologics.
ERJ Open Res
. 2021;7(2):00309–2020.
5.
Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma.
Eur Respir J
. 2018;51(4):1702536.
6.
Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function.
Adv Immunol
. 1986;39:177–253.
7.
McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma.
Front Med
. 2017;4:93.
8.
de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins.
ERJ Open Res
. 2015;1(1):00024–2015.
9.
Guo CL, Sun XM, Wang XW, Guo Q. Serum eosinophil cationic protein is a useful marker for assessing the efficacy of inhaled corticosteroid therapy in children with bronchial asthma.
Tohoku J Exp Med
. 2017;242(4):263–71.
10.
Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma.
Clin Exp Allergy
. 1998;28(2):233–40.
11.
Venge P. Monitoring the allergic inflammation.
Allergy
. 2004;59(1):26–32.
12.
Fujisawa T, Terada A, Atsuta J, Iguchi K, Kamiya H, Sakurai M. Clinical utility of serum levels of eosinophil cationic protein (ECP) for monitoring and predicting clinical course in childhood asthma.
Clin Exp Allergy
. 1998;28(1):19–25.
13.
Bartoli ML, Bacci E, Carnevali S, Cianchetti S, Dente FL, Di Franco A, et al. Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation.
Respir Med
. 2004;98(2):184–93.
14.
Boumendjel A, Tridon A, Messarah M, Ughetto S, Meharzi S, Boulakoud MS. Eosinophilic activity and bronchial hyperresponsiveness within an asthmatic paediatric population.
Allergol Immunopathol
. 2012;40(5):301–5.
15.
Sorkness C, McGill K, Busse WW. Evaluation of serum eosinophil cationic protein as a predictive marker for asthma exacerbation in patients with persistent disease.
Clin Exp Allergy
. 2002;32(9):1355–9.
16.
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma.
N Engl J Med
. 2011;365(12):1088–98.
17.
Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide.
Eur Respir Monograph
. 2010;49:1–31.
18.
Gaillard EA, Kuehni CE, Turner S, Goutaki M, Holden KA, de Jong CCM, et al. European respiratory society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.
Eur Respir J
. 2021;58:2004173.
19.
Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods.
Eur Respir J
. 1995;8(3):483–91.
20.
Futamura M, Ohya Y, Akashi M, Adachi Y, Odajima H, Akiyama K, et al. Age-related prevalence of allergic diseases in Tokyo schoolchildren.
Allergol Int
. 2011;60(4):509–15.
21.
Koller DY, Herouy Y, Götz M, Hagel E, Urbanek R, Eichler I. Clinical value of monitoring eosinophil activity in asthma.
Arch Dis Child
. 1995;73(5):413–7.
22.
Mogensen I, Alving K, Bjerg A, Borres MP, Hedlin G, Sommar J, et al. Simultaneously elevated exhaled nitric oxide and serum-eosinophil cationic protein relate to recent asthma events in asthmatics in a cross-sectional population-based study.
Clin Exp Allergy
. 2016;46(12):1540–8.
23.
Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review.
Respir Med
. 2007;101(4):696–705.
24.
Polavarapu M, Klonoff-Cohen H. Serum ECP as a diagnostic marker for asthma in children less than 5 years: a systematic review and meta-analysis.
Pediatr Pulmonol
. 2020;55(12):3243–51.
25.
Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease.
Clin Exp Allergy
. 1999;29(9):1172–86.
26.
Kato Y, Fujisawa T, Terada A, Iguchi K, Kamiya H. Mechanisms of eosinophil cationic protein release in the serum: role of adhesion molecules.
Int Arch Allergy Immunol
. 1999;120 Suppl 1(Suppl 1):60–4.
27.
Koh YY, Kang H, Kim CK. Ratio of serum eosinophil cationic protein/blood eosinophil counts in children with asthma: comparison between acute exacerbation and clinical remission.
Allergy Asthma Proc
. 2003;24(4):269–74.
28.
Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper.
Allergy
. 2019;74(10):1835–51.
29.
Zaigham S, Zhou X, Molin M, Sjolander A, Moverare R, Janson C, et al. Importance of type and degree of IgE sensitisation for defining fractional exhaled nitric oxide reference values.
Respir Med
. 2021;188:106621.
30.
Larche M. Changes in interferon-gamma production following specific allergen immunotherapy: biology vs methodology [editorial;comment].
Clin Exp Allergy
. 2000;30(3):297–300.
31.
Murray C, Foden P, Lowe L, Durrington H, Custovic A, Simpson A. Diagnosis of asthma in symptomatic children based on measures of lung function: an analysis of data from a population-based birth cohort study.
Lancet Child Adolesc Health
. 2017;1(2):114–23.
32.
Prehn A, Seger RA, Faber J, Torresani T, Molinari L, Gerber A, et al. The relationship of serum-eosinophil cationic protein and eosinophil count to disease activity in children with bronchial asthma.
Pediatr Allergy Immunol
. 1998;9(4):197–203.
33.
Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Lancet Respir Med
. 2021;9(10):1165–73.
34.
Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells.
Clin Exp Allergy
. 2008;38(6):936–46.
35.
Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Lancet Respir Med
. 2018;6(7):499–510.
36.
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma.
Am J Respir Crit Care Med
. 2009;180(5):388–95.
37.
Yamamoto-Hanada K, Borres MP, Aberg MK, Yang L, Fukuie T, Narita M, et al. IgE responses to multiple allergen components among school-aged children in a general population birth cohort in Tokyo.
World Allergy Organ J
. 2020;13(2):100105.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.